Clinical trials: IBS, Mixed Symptoms
Irritable Bowel Syndrome
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or…
- Trial name
- NCT03806127
- Testing
- Vibegron
- Where
- 41 sites in United States
- Volunteers
- 222 people
- Sponsor
- Urovant Sciences GmbH